Management of Male Factor Infertility

Prof. Muataz, Al-Ramahi, MD

Introduction

- Infertility: Inability to conceive of 12 months duration despite adequate unprotected intercourse
- 10-15% of couples
- Male factor contributes to 30-40% of cases
- It is defined by abnormal semen parameters but may be present even when the semen analysis is normal

Why to Evaluate ?

- Identify and treat the cause
- Detection of genetic abnormalities
- Identify underlying medical conditions

Indications for evaluation

- For couples who fail to achieve pregnancy after at least 12 months of regular unprotected intercourse
- Earlier evaluation:
 - Women older than 35 years
 - Medical history or physical examination
- Males having concerns about their future fertility

Initial evaluation

- Detailed reproductive history
- At least one semen analysis

Reproductive history

- Duration of infertility and prior fertility
- Coital frequency and timing
- Childhood illnesses and developmental history
- Systemic medical illnesses
- Previous surgery
- Medication and allergies
- Sexual history
- Exposures to gonadal toxins

Semen analysis

- Pre-test abstinence interval
- Method of collection
- Semen volume (> 1.5 ml)
- Sperm concentration (> 15 M/ml)
- Percent motile (40%)
- Forward progression (32%)
- Normal morphology (> 4%)

Defective parameters

Low volume

• Short abstinence period, hypogonadism

• Low volume, low pH, low fructose

- Ejaculatory duct obstruction
- Seminal vesicles produce 50% of semen volume, fructose and alkaline secretion

Oligospermia

• Likelihood of male infertility increases 5-folds when count <13.5 M/ml

• Asthenospermia

• Likelihood of male infertility increases 5-folds when motility <32%

Defective parameters

• Teratozoospermia

- Strict sperm morphology [Kruger] is the best predictor of sperm function (capacity to fertilize)
- Conventional fertilization
 - Highest (>90%) when $\geq 14\%$ normal forms
 - Lowest (7-8%) when $\leq 4\%$ normal forms

Hyperviscosity

- Associated at times with asthenospermia
- Suggests dysfunction in accessory glands
- Little importance

Complete evaluation

- Medical history
- Physical examination
- Tests and procedures

Endocrine evaluation

- Indications:
 - Low sperm concentration
 - Impaired sexual function
 - Clinical findings suggestive of specific endocrinopathy
- Hormonal evaluation (FSH, Te, LH, PRL, TSH)

Endocrine evaluation

- Hypogonadotropic hypogonadism [low test; low FSH]
 - Successful medical treatment
 - Combination of gonadotropins and HCG
- Eugonadotropic hypogonadism [low test; nl FSH]
 Aromatase inhibitors

Endocrine evaluation

Hypergonadotropic hypogonadism [high FSH] No beneficial medical treatment

• Eugonadotropic eugonadism [nl test; nl FSH]

• No beneficial medical treatment [androgens, gonadotropins, clomiphene citrate, tamoxifen, vit E, selenium, L-carnitine]

Post-ejaculatory Urinalysis

- Low-volume or absent antegrade ejaculation
 - Incomplete semen collection
 - Ejaculatory duct obstruction
 - Hypogonadism
 - CBAVD
 - Retrograde ejaculation

Other Tests

- Ultrasonography (TRUS, Scrotal USS)
- Quantitation of Leucocytes in semen
- Tests for Antisperm Antibodies
- Sperm Viability Tests

Sperm DNA Fragmentation Tests

- Denatured or damaged DNA that cannot be repaired
- Due to intrinsic or extrinsic factors
- Direct methods (Comet, TUNEL) analyze the number of breaks in DNA
- Indirect methods (SCSA) define abnormal chromatin structure
- It is not routinely recommended
- No treatment for abnormal DNA integrity
- Varicocele repair, antioxidants use may affect sperm DNA integrity
- Sperm retrieved from the testis has better DNA quality in patients with abnormal ejaculated sperm DNA integrity

Specialized Tests

- Sperm penetration assay
- Acrosome reaction of human sperm
- Biochemical tests (Sperm creatine kinase, ROS)
- Tests for selecting sperms for ICSI (Hyaluronic acid binding, apoptosis evaluation, IMSI)

Genetic Screening

- In men with non-obstructive azoospermia and severe oligozoospermia
- Genetic tests:
 - Karyotyping
 - Y-chromosome microdeletions
 - Cystic fibrosis gene mutation

Male Factor Treatment

• Treat the cause:

- Sexual dysfunction
- Hyperprolactinemia
- Thyroid disorders
- Medication

Hypogonadotropic Hypogonadism

Male Factor Treatment

- Antioxidants
- L-Arginine
- L-Carnitine
- Aromatase inhibitors

Male Factor Treatment

• <u>ART</u> - IUI - IVF (ICSI)

